Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/32575
Title: The Plant Derivative Compound A Inhibits the Production of Corticosteroid-resistant Chemokines by Airway Smooth Muscle Cells.
Authors: Gavrila, Adelina
Chachi, Latifa
Tliba, Omar
Brightling, Christopher
Amrani, Yassine
First Published: 21-Apr-2015
Publisher: American Thoracic Society
Citation: American Journal of Respiratory Cell and Molecular Biology, 2015, DOI: 10.1165/rcmb.2014-0477OC
Abstract: Preclinical models of human conditions including asthma showed the therapeutic potential of compound A (CpdA), a dissociated glucocorticoid (GC) receptor (GRα) ligand. Whether CpdA inhibits GC resistance, a central feature of severe asthma, has not been addressed. We investigated whether CpdA modulates cytokine-induced GC resistance in human airway smooth muscle (ASM) cells. Healthy and asthmatic ASM cells were treated with TNFα/IFNγ for 24 hr in the presence or absence of CpdA. ELISA and qPCR assays were used to assess the effect of CpdA on chemokine expression. Activation of GRα by CpdA was assessed by qPCR, immunostaining and receptor antagonism using RU486. An effect of CpdA on the transcription factor IRF-1 was investigated using immunoblot, immunostaining and siRNA knockdown. CpdA inhibited production of fluticasone-resistant chemokines CCL5, CX3CL1, and CXCL10 at protein and mRNA levels in both asthmatic and healthy cells. CpdA failed to induce expression of Glucocorticoid-induced Leucine Zipper (GILZ) while transiently inducing MAPK phosphatase 1 (MKP-1) at both mRNA and protein levels. CpdA inhibitory action was not associated with GRαnuclear translocation nor prevented by RU486 antagonism. Activation of IRF-1 by TNFα/IFNγ was inhibited by CpdA. IRF-1 siRNA knockdown reduced cytokine-induced CCL5 and CX3CL1 production. siRNA MKP-1 prevented the inhibitory effect of CpdA on cytokine-induced CXCL10 production. For the first time, we show that CpdA inhibits the production of GC-resistant chemokines via GRα-independent mechanisms involving the inhibition of IRF-1 and up-regulation of MKP-1. Thus, targeting CpdA sensitive pathways in ASM cells represents an alternative therapeutic approach to treat GC resistance in asthma.
DOI Link: 10.1165/rcmb.2014-0477OC
ISSN: 1044-1549
eISSN: 1535-4989
Links: http://www.atsjournals.org/doi/10.1165/rcmb.2014-0477OC#.VZ-ZBUbK-5I
http://hdl.handle.net/2381/32575
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2015, American Thoracic Society. Deposited with reference to the publisher’s archiving policy available on the SHERPA/RoMEO website.
Appears in Collections:Published Articles, Dept. of Infection, Immunity and Inflammation

Files in This Item:
File Description SizeFormat 
Figures Gavrila et al (2).pptxPost-review (final submitted)3.34 MBUnknownView/Open
Revised Gavrila MS 2013 (clean version).pdfPost-review (final submitted)386.16 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.